GroupKALSHI

Event GroupKALSHIScience and Technology

Will the FDA approve VERVE-102?

Total Volume

$0.00

Events

Markets

Trade on Kalshi

Will the FDA approve VERVE-102?

Vol

$0.00

Events

Markets

Kalshi

Platform StatsQuick Platform Comparison

Polymarket

markets · $0.00

Kalshi

markets · $0.00

Price Spread

0.0%avg

max 0.0%

Arbitrage

of 0 cross-platform

Price ChartMatched Markets Price Graph

6 markets tracked

Will the FDA approve VERVE-102 before Jan 1, 2035?

No data available

Single-Platform Markets(6)

Market	Platform	Price
Will the FDA approve VERVE-102 before Jan 1, 2035?	Kalshi	83%
Will the FDA approve VERVE-102 before Jan 1, 2034?	Kalshi	78%
Will the FDA approve VERVE-102 before Jan 1, 2033?	Kalshi	75%
Will the FDA approve VERVE-102 before Jan 1, 2032?	Kalshi	71%
Will the FDA approve VERVE-102 before Jan 1, 2031?	Kalshi	65%
Will the FDA approve VERVE-102 before Jan 1, 2030?	Kalshi	54%

AI Analysis

Trader mode: Actionable analysis for identifying opportunities and edge

83%

Top Probability

$0.00

Volume

Markets

Platforms

About This Event

VERVE-102 If the FDA approves VERVE-102 for marketing before Jan 1, X then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application, NDA, or Biologics License Application, BLA, For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA, sNDA, or supplemental BLA, sBLA, for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application, ANDA, For biosi

AI-generated analysis based on market data. Not financial advice.

Custom AI Analysis Prompt

Tap to expand

Open in:ChatGPT Claude Gemini Grok DeepSeek

**Role:** Expert Prediction Market Analyst & Trader
**Objective:** Analyze the provided betting market data to deliver actionable insights, identify mispricings, and perform scenario analysis.
**Current Date:** Friday, July 10, 2026
**Context:** Prediction markets (Polymarket/Kalshi) are binary option markets where price (1-99) equals implied probability (1%-99%).

---

## 1. Event Snapshot
**Event:** Will the FDA approve VERVE-102?
**Category:** Science and Technology | **Status:** active
**Resolution Date:** N/A (Unknown)
**Time Pressure:** Unknown

**Description:** VERVE-102

If the FDA approves VERVE-102 for marketing before Jan 1, X then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application, NDA, or Biologics License Application, BLA, For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA, sNDA, or supplemental BLA, sBLA, for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application, ANDA, For biosi

**Resolution Criteria (Sample):**
"If the FDA approves VERVE-102 for marketing before Jan 1, 2035, then the market resolves to Yes. Secondary rules: An approval is defined as:

For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking n"

## 2. Market liquidity & Volume
* **Total Volume:** $0
* **Total Liquidity:** $0
* **Activity Level:** Low Activity (Vol/Liq Ratio: 0.00)

## 3. Market Data (Prices & Odds)
### 1. Will the FDA approve VERVE-102 before Jan 1, 2035?
- **Kalshi** (End: Jan 8, 2035): Vol $0
  DATA: [Yes: 82.5% (0.0%)] | [No: 17.5% (0.0%)]

### 2. Will the FDA approve VERVE-102 before Jan 1, 2034?
- **Kalshi** (End: Jan 8, 2034): Vol $0
  DATA: [Yes: 77.5% (0.0%)] | [No: 22.5% (0.0%)]

### 3. Will the FDA approve VERVE-102 before Jan 1, 2033?
- **Kalshi** (End: Jan 8, 2033): Vol $0
  DATA: [Yes: 75.0% (0.0%)] | [No: 25.0% (0.0%)]

### 4. Will the FDA approve VERVE-102 before Jan 1, 2032?
- **Kalshi** (End: Jan 8, 2032): Vol $0
  DATA: [Yes: 71.0% (0.0%)] | [No: 29.0% (0.0%)]

### 5. Will the FDA approve VERVE-102 before Jan 1, 2031?
- **Kalshi** (End: Jan 8, 2031): Vol $0
  DATA: [Yes: 64.5% (0.0%)] | [No: 35.5% (0.0%)]

### 6. Will the FDA approve VERVE-102 before Jan 1, 2030?
- **Kalshi** (End: Jan 8, 2030): Vol $0
  DATA: [Yes: 54.5% (0.0%)] | [No: 45.5% (0.0%)]

---

## Analysis Instructions
Please provide a structured analysis using the following template:

### 1. Executive Summary
*   **Verdict:** [Most Likely Outcome]
*   **Confidence:** [0-100]%
*   **Timeframe:** [Immediate / Short-term / Long-term]
*   **Actionable Trade:** [Buy YES / Buy NO / Stay Away] (Include entry price target if applicable)
*   **Rationale:** 2-sentence summary of the core thesis.

### 2. Scenario Analysis
*   **Bull Case (Why YES goes up):** List specific catalysts or data points.
*   **Bear Case (Why YES goes down):** List specifics.
*   **Invalidation Point:** What happens to prove your thesis wrong?

### 3. Market Mechanics & Risks
*   **Liquidity/Volume Analysis:** Is the market efficient? Is it easy to exit?
*   **Cross-Platform Arbitrage:** (If applicable) Is the spread tradeable after fees?
*   **Time Decay:** How does time passing affect this position?

### 4. Signal Scores (0-100)
*   **Momentum:** [Score] (Price trend & velocity)
*   **Conviction:** [Score] (Volume backing the move)
*   **Information Edge:** [Score] (Likelihood of non-public info affecting price)
*   **Risk/Reward:** [Score] (Potential upside vs downside)

**Constraints:**
- Be direct and objective.
- Use bullet points for readability.
- If data is conflicting or insufficient, explicitly state "Low Confidence".

Tap text to select all

Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.

KALSHIScience and Technology

Will the FDA approve VERVE-102?

Volume$0.00

Markets6

6 of 6

Sort:

KALSHI

Will the FDA approve VERVE-102 before Jan 1, 2035?

KALSHI

KKalshi

Yes 82.5¢No 17.5¢

KALSHIHealth

Will the FDA approve VERVE-102 before Jan 1, 2035?

If the FDA approves VERVE-102 for marketing before Jan 1, 2035, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking n

KALSHI

Will the FDA approve VERVE-102 before Jan 1, 2034?

KALSHI

KKalshi

Yes 77.5¢No 22.5¢

KALSHIHealth

Will the FDA approve VERVE-102 before Jan 1, 2034?

If the FDA approves VERVE-102 for marketing before Jan 1, 2034, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking n

KALSHI

Will the FDA approve VERVE-102 before Jan 1, 2033?

KALSHI

KKalshi

Yes 75.0¢No 25.0¢

KALSHIHealth

Will the FDA approve VERVE-102 before Jan 1, 2033?

If the FDA approves VERVE-102 for marketing before Jan 1, 2033, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking n

KALSHI

Will the FDA approve VERVE-102 before Jan 1, 2032?

KALSHI

KKalshi

Yes 71.0¢No 29.0¢

KALSHIHealth

Will the FDA approve VERVE-102 before Jan 1, 2032?

If the FDA approves VERVE-102 for marketing before Jan 1, 2032, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking n

KALSHI

Will the FDA approve VERVE-102 before Jan 1, 2031?

KALSHI

KKalshi

Yes 64.5¢No 35.5¢

KALSHIHealth

Will the FDA approve VERVE-102 before Jan 1, 2031?

If the FDA approves VERVE-102 for marketing before Jan 1, 2031, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking n

No related news found

Discussion

0 Comments

Market Insights

Average Yes Price

71¢

Kalshi

Arbitrage Opps

Cross-Platform

Embed Widget

Add this market to your website

Volume

Platforms

HTML

<iframe src="https://predictpedia.com/embed/MhgtgW" width="400" height="160" frameborder="0" style="border-radius: 8px; max-width: 100%;" title="Will the FDA approve VERVE-102?"></iframe>

Trade This Market

Trade on Kalshi

Will the FDA approve VERVE-102?

Will the FDA approve VERVE-102?

Platform StatsQuick Platform Comparison

Price ChartMatched Markets Price Graph

Will the FDA approve VERVE-102 before Jan 1, 2035?

AI Analysis

About This Event

Custom AI Analysis Prompt

Educational Context

Events (1)

Will the FDA approve VERVE-102?

Markets (6)

Will the FDA approve VERVE-102 before Jan 1, 2035?

Will the FDA approve VERVE-102 before Jan 1, 2035?

Will the FDA approve VERVE-102 before Jan 1, 2034?

Will the FDA approve VERVE-102 before Jan 1, 2034?

Will the FDA approve VERVE-102 before Jan 1, 2033?

Will the FDA approve VERVE-102 before Jan 1, 2033?

Will the FDA approve VERVE-102 before Jan 1, 2032?

Will the FDA approve VERVE-102 before Jan 1, 2032?

Will the FDA approve VERVE-102 before Jan 1, 2031?

Will the FDA approve VERVE-102 before Jan 1, 2031?

Related News & Context

Discussion

Market Insights

Share

Embed Widget

Trade This Market

Platform StatsQuick Platform Comparison

Price ChartMatched Markets Price Graph

Will the FDA approve VERVE-102 before Jan 1, 2035?

Custom AI Analysis Prompt

Will the FDA approve VERVE-102?

Will the FDA approve VERVE-102 before Jan 1, 2035?

Will the FDA approve VERVE-102 before Jan 1, 2035?

Will the FDA approve VERVE-102 before Jan 1, 2034?

Will the FDA approve VERVE-102 before Jan 1, 2034?

Will the FDA approve VERVE-102 before Jan 1, 2033?

Will the FDA approve VERVE-102 before Jan 1, 2033?

Will the FDA approve VERVE-102 before Jan 1, 2032?

Will the FDA approve VERVE-102 before Jan 1, 2032?

Will the FDA approve VERVE-102 before Jan 1, 2031?

Will the FDA approve VERVE-102 before Jan 1, 2031?

Related News & Context

Discussion

Share

Embed Widget